DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it expects to report revenue of approximately $2.6 million and $5.3 million for the second quarter and year-to-date in 2010, respectively. These revenues represent increases of 45 percent and 18 percent for each of the respective periods over the same periods in 2009. Increased sales volume of the Company’s base gamma detection systems, offset by slight price decreases, accounted for the increases in both periods.
